Dr Clara Alsinet-Armengol | Postdoctoral Fellow

Alsinet-Armengol, Clara

I am a postdoctoral fellow in the Experimental Cancer Genetics team. May main focus is the functional characterization of known and novel cancer genes using human induced Pluripotent Stem Cells and CRISPR-Cas9.

High-throughput sequencing efforts are uncovering the mutation profiles associated to cancer in a comprehensive and unbiased fashion. Nevertheless, further analyses of the identified alterations are necessary to highlight those genes implicated in disease development, as well as, those with therapeutical potential. Recently, the team generated a list of candidate genes commonly lost in cancer based on the analysis of >7500 tumor samples across 28 tissues. To uncover the functional impact of the loss of these genes we are generating a panel of knock-out isogenic iPS cell lines using CRISPR-Cas9 and we will perform high-throughput genetic and drug screenings on these lines. Overall, this study will identify molecular interactions of the selected cancer-related genes thus revealing potential new roles and candidate therapies.

Publications

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Letter: Acid secretion by gastric mucous membrane.

    Durbin RP

    The American journal of physiology 1975;229;6;1726

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Mechanisms of disposal of acid and alkali in rabbit duodenum.

    Fiddian-Green RG and Silen W

    The American journal of physiology 1975;229;6;1641-8

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Oxygenation of frog gastric mucosa in vitro.

    Kidder GW and Montgomery CW

    The American journal of physiology 1975;229;6;1510-3

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Coronary vascular and myocardial responses to carotid body stimulation in the dog.

    Ehrhart IC, Parker PE, Weidner WJ, Dabney JM, Scott JB and Haddy FJ

    The American journal of physiology 1975;229;3;754-60

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Effect of sodium nitrate loading on electrolyte transport by the renal tubule.

    Kahn T, Bosch J, Levitt MF and Goldstein MH

    The American journal of physiology 1975;229;3;746-53

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Acid-base balance in amphibian gastric mucosa.

    Silen W, Machen TE and Forte JG

    The American journal of physiology 1975;229;3;721-30

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Effect of pH on ionic exchange and function in rat and rabbit myocardium.

    Poole-Wilson PA and Langer GA

    The American journal of physiology 1975;229;3;570-81

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial.

    Bland RD, Clarke TL and Harden LB

    American journal of obstetrics and gynecology 1976;124;3;263-7

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp.

    Stamm O, Latscha U, Janecek P and Campana A

    American journal of obstetrics and gynecology 1976;124;2;193-5

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Review of drug treatment for Down's syndrome persons.

    Share JB

    American journal of mental deficiency 1976;80;4;388-93

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Use of the latent image technique to develop and evaluate problem-solving skills.

    Schwabbauer ML

    The American journal of medical technology 1975;41;12;457-62

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Biochemical and electrophoretic studies of erythrocyte pyridoxine kinase in white and black Americans.

    Chern CJ and Beutler E

    American journal of human genetics 1976;28;1;9-17

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes.

    Korelitz BI and Sommers SC

    The American journal of gastroenterology 1975;64;5;365-70

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Management of life-threatening asthma with intravenous isoproterenol infusions.

    Parry WH, Martorano F and Cotton EK

    American journal of diseases of children (1960) 1976;130;1;39-42

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Nutrition education in the medical school curriculum: a proposal for action: a curriculum design.

    Frankle RT

    The American journal of clinical nutrition 1976;29;1;105-9

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Rapid in-office and in-vivo desensitization of an injection phobia utilizing hypnosis.

    Daniels LK

    The American journal of clinical hypnosis 1976;18;3;200-3

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.

    Fowler NO, McCall D, Chou TC, Holmes JC and Hanenson IB

    The American journal of cardiology 1976;37;2;223-30

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • V.I. Gavrilov.

    No authors listed

    Acta virologica 1975;19;6;510

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Elizaveta Nilolaevna Levkovich-75th birthday.

    Pogodina VV

    Acta virologica 1975;19;6;509

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • On the problem of oncogene of tumour viruses.

    Mekler LB

    Acta virologica 1975;19;6;501-8

  • Unique genomic profile of fibrolamellar hepatocellular carcinoma.

    Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K et al.

    Gastroenterology 2015;148;4;806-18.e10

  • DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

    Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21;4;925-33

  • One patient, two lesions, two oncogenic drivers of gastric cancer.

    Alsinet C, Ranzani M and Adams DJ

    Genome biology 2014;15;8;444

  • UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

    Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A et al.

    Cancer cell 2014;25;2;196-209

  • VEGF signaling in cancer treatment.

    Sia D, Alsinet C, Newell P and Villanueva A

    Current pharmaceutical design 2014;20;17;2834-42

  • Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies?

    Hernandez-Gea V, Alsinet C and Llovet JM

    Journal of hepatology 2013;59;4;882-4

  • Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

    Alsinet C, Cornella H and Villanueva A

    Future oncology (London, England) 2013;9;6;767-70

  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

    Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J et al.

    Gastroenterology 2013;144;4;829-40

  • Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.

    Keng VW, Sia D, Sarver AL, Tschida BR, Fan D et al.

    Hepatology (Baltimore, Md.) 2013;57;1;120-30

  • Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.

    Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y et al.

    Gastroenterology 2012;143;6;1660-1669.e7

  • Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18;18;4997-5007

  • Gene signatures in the management of hepatocellular carcinoma.

    Hoshida Y, Moeini A, Alsinet C, Kojima K and Villanueva A

    Seminars in oncology 2012;39;4;473-85

  • Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

    Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y et al.

    Journal of hepatology 2012;56;6;1343-50

  • Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

    Alsinet C, Villanueva A and Llovet JM

    Journal of hepatology 2012;56;5;1198-200

  • [Genomic prognostic markers in hepatocellular carcinoma].

    Alsinet C and Villanueva A

    Gastroenterología y hepatología 2012;35;2;94-101

  • microRNAs and the MYC network: a major piece in the puzzle of liver cancer.

    Toffanin S, Alsinet C, Cornella H, Sia D and Llovet JM

    Gastroenterology 2011;140;7;2138-40

  • Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al.

    Gastroenterology 2011;140;5;1501-12.e2

  • MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

    Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L et al.

    Gastroenterology 2011;140;5;1618-28.e16

  • Molecular pathogenesis of hepatocellular carcinoma.

    Cornellà H, Alsinet C and Villanueva A

    Alcoholism, clinical and experimental research 2011;35;5;821-5

  • New strategies in hepatocellular carcinoma: genomic prognostic markers.

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16;19;4688-94

  • Molecular approaches to treatment of hepatocellular carcinoma.

    Lachenmayer A, Alsinet C, Chang CY and Llovet JM

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3;S264-72

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY et al.

    Journal of hepatology 2010;52;4;550-9

  • Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B et al.

    Journal of hepatology 2009;51;4;725-33

  • Pivotal role of mTOR signaling in hepatocellular carcinoma.

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S et al.

    Gastroenterology 2008;135;6;1972-83, 1983.e1-11

  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al.

    Cancer research 2008;68;16;6779-88

  • Precipitation of phase I antigen of Coxiella burnetii by sodium sulfite.

    Wachter RF, Briggs GP and Pedersen CE

    Acta virologica 1975;19;6;500

Alsinet-Armengol, Clara
Clara's Timeline
2013

Start of my first Postdoc at the Wellcome Trust Sanger Institute in Cambridge, UK

PhD in Biomedicine from the University of Barcelona

2011

Visiting Researcher at the Icahn School of Medicine at Mount Sinai, New York

2008

Post-Graduate in Molecular and Cellular Biology at the University of Barcelona

2006

Education Aborad Program student at the University of California, Davis

2005

Major in Biotechnology at the Autonomous University of Barcelona